



ADULT Medication Monograph

FUROSEMIDE (FRUSEMIDE)




This document should be read in conjunction with this [DISCLAIMER](#)

[Formulary: Unrestricted](#)

Class	Loop diuretic
Presentation	Ampoule: 20mg/2mL, 250mg/25mL Tablet: 40mg, 500mg Oral Suspension: 10mg/mL (100mL) (Ethanol Free: KEMH Only)
Storage	Store at room temperature, below 25°C
Dose	<u>Acute Cardiac Failure in Obstetrics</u> Refer to Clinical Practice Guideline: Cardiac Disease <u>Oedema</u> Oral: Initially 20–40 mg once or twice daily, adjusted according to clinical response to maintenance dose of 20–400 mg daily. Maximum dose 1 g daily. IV/IM: 20–40 mg; repeat at intervals of at least 2 hours until the desired diuretic effect is obtained (increase dose by 20 mg each time if necessary). <u>Hypercalcaemia</u> IV: 80–100 mg every 1–2 hours.
Administration	<u>Oral:</u> <ul style="list-style-type: none">• Usually taken in the morning.• If twice a day dosing, take the first dose in the morning and the second dose at lunchtime, or before 2pm. <u>IM injection:</u> <ul style="list-style-type: none">• Suitable, however IV route preferred.

	<ul style="list-style-type: none"> • Inject undiluted. <p><u>Subcut injection:</u></p> <ul style="list-style-type: none"> • Suitable in palliative care patients as an intermittent injection or as a continuous subcutaneous infusion. <p><u>IV injection:</u></p> <ul style="list-style-type: none"> • Inject doses up to and including 80 mg slowly over 3 to 5 minutes. Higher doses must be given by slow IV infusion (see below). <p><u>IV infusion:</u></p> <ul style="list-style-type: none"> • Dilute with 50-250mL of a compatible fluid to a concentration of 1 mg/mL whenever possible. • Infuse at a maximum rate of 4 mg/minute. • Note: More concentrated solutions or the undiluted solution may be infused in fluid-restricted patients (using a rate controlled infusion pump). <p><i>Compatible fluids: Glucose 5%, Hartmann's, sodium chloride 0.9%</i></p>
Pregnancy	<p>1st Trimester: Consider alternative 2nd Trimester: Consider alternative 3rd Trimester: Consider alternative</p> <p>For more information, please contact KEMH Obstetric Medicines Information Service.</p>
Breastfeeding	<p>Consider alternative. Furosemide may reduce milk supply</p> <p>For more information, please contact KEMH Obstetric Medicines Information Service.</p>
Monitoring	<p>Weight, Urea & Electrolytes, Creatinine.</p> <p>Ototoxicity with IV administration – tinnitus, vertigo and deafness.</p>
Clinical Guidelines and Policies	<p>KEMH Pharmaceutical & Medicines Management Guideline: Medication Administration</p> <p>Formulary One (WA Health Medicines Formulary): Formulary One</p> <p>KEMH Clinical Practice Guidelines: Cardiac Disease</p>
References	<p>Australian Medicines Handbook. Frusemide. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2020 [cited 2020 Mar 5]. Available</p>

	<p>from: https://amhonline.amh.net.au/</p> <p>Society of Hospital Pharmacists of Australia. Frusemide. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2020 [cited 2020 Mar 5]. Available from: http://aidh.hcn.com.au</p> <p>The Royal Women's Hospital. Furosemide. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2020 [cited 2020 Mar 5]. Available from: https://thewomenspbmg.org.au/</p>
--	--

Keywords:	Furosemide, Frusemide, Diuretic, oedema, edema, hypercalcaemia		
Publishing:	<input checked="" type="checkbox"/> Intranet <input checked="" type="checkbox"/> Internet		
Document owner:	Chief Pharmacist		
Author / Reviewer:	KEMH Pharmacy Department		
Date first issued:	December 2014	Version:	4.0
Last reviewed:	Mar 2020	Next review date:	March 2023
Endorsed by:	Medicines and Therapeutics Committee	Date:	March 2020
Standards Applicable:	NSQHS Standards: 1  Governance, 4  Medication Safety, 8  Acute Deterioration		

Printed or personally saved electronic copies of this document are considered uncontrolled.

Access the current version from the WNHS website.

For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au

© Department of Health Western Australia 2020